Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1051 to 1065 of 1877 results for do not dos

  1. Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)

    Evidence-based recommendations on chlormethine gel (Ledaga) for treating early-stage mycosis fungoides-type cutaneous T-cell lymphoma in adults.

    Technology appraisal guidance
    Published
    18 August 2021
    View recommendations

    Sections for TA720

  2. Pegaspargase for treating acute lymphoblastic leukaemia (TA408)

    Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA408

  3. Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

    Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.

    Technology appraisal guidance
    Published
    22 February 2017
    View recommendations

    Sections for TA432

  4. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)

    Evidence-based recommendations on botulinum toxin type A (Botox) for preventing headaches in adults with chronic migraine.

    Technology appraisal guidance
    Published
    27 June 2012
    View recommendations

    Sections for TA260

  5. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

    Technology appraisal guidance
    Published
    26 June 2013
    View recommendations

    Sections for TA290

  6. Transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair (HTG593)

    Evidence-based recommendations on transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair in adults. This involves inserting a bioprosthetic mitral valve into an existing mitral valve ring to treat a leaking mitral valve, without needing repeat open heart surgery.

    HealthTech guidance
    Published
    22 September 2021
    View recommendations

    Sections for HTG593

  7. Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis (HTG592)

    Evidence-based recommendations on transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis in adults. This involves inserting a new valve inside a failed bioprosthetic valve to replace the faulty one without needing repeat open heart surgery.

    HealthTech guidance
    Published
    22 September 2021
    View recommendations

    Sections for HTG592

  8. How we develop technology appraisal guidance

    A step-by-step summary about how we develop our technology appraisal guidance.

  9. Laser correction of refractive error following non-refractive ophthalmic surgery (HTG256)

    Evidence-based recommendations on laser correction of refractive error following non-refractive ophthalmic surgery. This involves changing the shape of the cornea, so that light rays are more precisely directed onto the retina.

    HealthTech guidance
    Published
    23 March 2011
    View recommendations

    Sections for HTG256

  10. Thoracoscopically assisted mitral valve surgery (HTG157)

    Evidence-based recommendations on thoracoscopically assisted mitral valve surgery. This involves repairing a defective valve through one or more small incisions between the ribs rather than one large incision through the breastbone (sternum).

    HealthTech guidance
    Published
    12 December 2007
    View recommendations

    Sections for HTG157

  11. Modular updates

    Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.

  12. Optimal interventional and conservative treatments at different stages of disease:- What is the optimal treatment (compression, surgery, endothermal ablation or foam sclerotherapy) for varicose veins at each of the CEAP stages, that is CEAP stages 2–3, CEAP stage 4 and CEAP stages 5–6?

    different stages of disease. Hence current treatment recommendations, which do not differentiate between patients with varicose veins at...

    Research recommendation
    Published
    9 June 2015

  13. Cardiovascular disease: identifying and supporting people most at risk of dying early (PH15)

    This guideline covers the risk of early death from heart disease and other smoking-related illnesses. It aims to reduce the number of people who are disadvantaged dying prematurely by ensuring people have better access to flexible, well-coordinated treatment and support.

    Public health guideline
    Published
    24 September 2008
    View recommendations

    Sections for PH15

  14. Skin cancer (QS130)

    This quality standard covers preventing, assessing, diagnosing and managing skin cancer (melanoma and non-melanoma skin cancer). It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    24 January 2024
    View quality statements

    Sections for QS130

  15. Social care for older people with multiple long-term conditions (QS132)

    This quality standard covers the planning and delivery of social care and support for older people (aged 65 and over) with multiple long-term conditions. It includes people living in their own homes, in specialist settings or in care homes, both those who receive support with funding for their social care and those who do not. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    21 September 2016
    View quality statements

    Sections for QS132